FASENRA Regulatory Postmarketing Surveillance in Korea

Study identifier:D3250R00043

ClinicalTrials.gov identifier:NCT05091333

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

FASENRA Regulatory Postmarketing Surveillance in Korea

Medical condition

asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

230

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 11 Mar 2022
Estimated Primary Completion Date: 31 Jan 2025
Estimated Study Completion Date: 31 Jan 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria